Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Canva, Nimbus Therapeutics, and 370+ companies. 5-min read every Tuesday.
Canva is the world's leading design platform with 250M+ users — valued at $48B with $770M raised. Track IPO timeline, funding rounds, and readiness score.
| Industry | Design & Creative |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $42B |
| Total Funding | $770M |
| Headquarters | Sydney, Australia |
Structure-based drug design company using computational tools to develop precision medicines.
| Industry | Biotechnology |
| Stage | Series D |
| IPO Status | Private |
| Valuation | $2B |
| Total Funding | $475M |
| Headquarters | Cambridge, MA |
Canva is valued at $42B. Nimbus Therapeutics is valued at $2B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Canva has raised $770M. Nimbus Therapeutics has raised $475M.
Canva is currently private. Nimbus Therapeutics is currently private. Track both on TechStackIPO for S-1 filings and IPO announcements.
Canva operates in Design & Creative, while Nimbus Therapeutics operates in Biotechnology.
Canva is a Design & Creative company valued at $42B with $770M raised. Nimbus Therapeutics is a Biotechnology company valued at $2B with $475M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Canva and Nimbus Therapeutics through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.